{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:32:05Z","timestamp":1791347525121,"version":"4.3.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2012,4,26]],"date-time":"2012-04-26T00:00:00Z","timestamp":1335398400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1038\/bjc.2012.142","type":"journal-article","created":{"date-parts":[[2012,4,26]],"date-time":"2012-04-26T22:45:19Z","timestamp":1335480319000},"page":"1742-1752","source":"Crossref","is-referenced-by-count":29,"title":["Therapy of chronic myeloid leukaemia can benefit from the activation of stem cells: simulation studies of different treatment combinations"],"prefix":"10.1038","volume":"106","author":[{"given":"I","family":"Glauche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Thielecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M AG","family":"Essers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Trumpp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Roeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,4,26]]},"reference":[{"issue":"12","key":"BFbjc2012142_CR1","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/nrd2422","volume":"6","author":"EC Borden","year":"2007","unstructured":"Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR (2007) Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 6(12): 975\u2013990","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"BFbjc2012142_CR2","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1046\/j.1365-2141.1999.01749.x","volume":"107","author":"S Branford","year":"1999","unstructured":"Branford S, Hughes TP, Rudzki Z (1999) Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol 107(3): 587\u2013599","journal-title":"Br J Haematol"},{"issue":"3","key":"BFbjc2012142_CR3","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/cncr.25438","volume":"117","author":"J Cortes","year":"2010","unstructured":"Cortes J, Quintas-Cardama A, Jones D, Ravandi F, Garcia-Manero G, Verstovsek S, Koller C, Hiteshew J, Shan J, O'Brien S, Kantarjian H (2010) Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor. Cancer 117(3): 572\u2013580","journal-title":"Cancer"},{"issue":"6","key":"BFbjc2012142_CR4","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2(6): 561\u2013566","journal-title":"Nat Med"},{"issue":"6","key":"BFbjc2012142_CR5","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/leu.2009.43","volume":"23","author":"MW Drummond","year":"2009","unstructured":"Drummond MW, Heaney N, Kaeda J, Nicolini FE, Clark RE, Wilson G, Shepherd P, Tighe J, McLintock L, Hughes T, Holyoake TL (2009) A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response. Leukemia 23(6): 1199\u20131201","journal-title":"Leukemia"},{"issue":"7240","key":"BFbjc2012142_CR6","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/nature07815","volume":"458","author":"MA Essers","year":"2009","unstructured":"Essers MA, Offner S, Blanco-Bose WE, Waibler Z, Kalinke U, Duchosal MA, Trumpp A (2009) IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 458(7240): 904\u2013908","journal-title":"Nature"},{"issue":"5","key":"BFbjc2012142_CR7","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.molonc.2010.06.001","volume":"4","author":"MA Essers","year":"2010","unstructured":"Essers MA, Trumpp A (2010) Targeting leukemic stem cells by breaking their dormancy. Mol Oncol 4(5): 443\u2013450","journal-title":"Mol Oncol"},{"issue":"9","key":"BFbjc2012142_CR8","doi-asserted-by":"publisher","first-page":"e1000503","DOI":"10.1371\/journal.pcbi.1000503","volume":"5","author":"J Foo","year":"2009","unstructured":"Foo J, Drummond MW, Clarkson B, Holyoake T, Michor F (2009) Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib. PLoS Comput Biol 5(9): e1000503","journal-title":"PLoS Comput Biol"},{"issue":"4","key":"BFbjc2012142_CR9","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/sj.bjc.6603603","volume":"96","author":"I Glauche","year":"2007","unstructured":"Glauche I, Horn M, Roeder I (2007) Leukaemia stem cells: hit or miss? Br J Cancer 96(4): 677\u2013678; author reply 679\u2013680","journal-title":"Br J Cancer"},{"issue":"3","key":"BFbjc2012142_CR10","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.beha.2009.08.001","volume":"22","author":"JM Goldman","year":"2009","unstructured":"Goldman JM (2009) Treatment strategies for CML. Best Pract Res Clin Haematol 22(3): 303\u2013313","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"BFbjc2012142_CR11","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood.V99.1.319","volume":"99","author":"SM Graham","year":"2002","unstructured":"Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, Holyoake TL (2002) Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99(1): 319\u2013325","journal-title":"Blood"},{"issue":"22","key":"BFbjc2012142_CR12","first-page":"340","volume":"114","author":"F Guilhot","year":"2009","unstructured":"Guilhot F, Preudhomme C, Guilhot J, Mahon F-X, Nicolini FE, Rigual-Huguet F, Legros L, Guerci A, Rea D, Coiteux V, Maloisel F, Gardembas M, Bulabois C-E, Berger MG (2009) Significant higher rates of undetectable molecular residual disease and molecular responses with pegylated form of interferon a2a in combination with imatinib (IM) for the treatment of newly diagnosed chronic phase (CP) chronic myeloid leukaemia (CML) patients (pts): confirmatory results at 18 months of part 1 of the spirit phase III randomized trial of the french CML group (FI LMC). ASH Annu Meeting Abstracts 114(22): 340","journal-title":"ASH Annu Meeting Abstracts"},{"issue":"6","key":"BFbjc2012142_CR13","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, Goldman JM, Muller MC, Radich JP, Rudoltz M, Mone M, Gathmann I, Hughes TP, Larson RA (2009) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23(6): 1054\u20131061","journal-title":"Leukemia"},{"issue":"1\u20132","key":"BFbjc2012142_CR14","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1159\/000118786","volume":"188","author":"M Horn","year":"2008","unstructured":"Horn M, Loeffler M, Roeder I (2008) Mathematical modeling of genesis and treatment of chronic myeloid leukemia. Cells Tissues Organs 188(1\u20132): 236\u2013247","journal-title":"Cells Tissues Organs"},{"issue":"9","key":"BFbjc2012142_CR15","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1093\/jnci\/djk150","volume":"99","author":"X Jiang","year":"2007","unstructured":"Jiang X, Saw KM, Eaves A, Eaves C (2007) Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. J Natl Cancer Inst 99(9): 680\u2013693","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"BFbjc2012142_CR16","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1158\/1078-0432.CCR-05-0429","volume":"12","author":"HG Jorgensen","year":"2006","unstructured":"Jorgensen HG, Copland M, Allan EK, Jiang X, Eaves A, Eaves C, Holyoake TL (2006) Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate. Clin Cancer Res 12(2): 626\u2013633","journal-title":"Clin Cancer Res"},{"issue":"24","key":"BFbjc2012142_CR17","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Huguet F, Boque C, Chuah C, Bleickardt E, Bradley-Garelik MB, Zhu C, Szatrowski T, Shapiro D, Baccarani M (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362(24): 2260\u20132270","journal-title":"N Engl J Med"},{"issue":"27","key":"BFbjc2012142_CR18","doi-asserted-by":"publisher","first-page":"9714","DOI":"10.1073\/pnas.0501870102","volume":"102","author":"NL Komarova","year":"2005","unstructured":"Komarova NL, Wodarz D (2005) Drug resistance in cancer: principles of emergence and prevention. Proc Natl Acad Sci USA 102(27): 9714\u20139719","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"BFbjc2012142_CR19","doi-asserted-by":"publisher","first-page":"e990","DOI":"10.1371\/journal.pone.0000990","volume":"2","author":"NL Komarova","year":"2007","unstructured":"Komarova NL, Wodarz D (2007) Effect of cellular quiescence on the success of targeted CML therapy. PLoS One 2(10): e990","journal-title":"PLoS One"},{"issue":"4","key":"BFbjc2012142_CR20","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1053\/j.seminhematol.2010.06.005","volume":"47","author":"P La Rosee","year":"2010","unstructured":"La Rosee P, Deininger MW (2010) Resistance to imatinib: mutations and beyond. Semin Hematol 47(4): 335\u2013343","journal-title":"Semin Hematol"},{"issue":"11","key":"BFbjc2012142_CR21","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B, Etienne G, Reiffers J, Rousselot P (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11(11): 1029\u20131035","journal-title":"Lancet Oncol"},{"issue":"7046","key":"BFbjc2012142_CR22","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/nature03669","volume":"435","author":"F Michor","year":"2005","unstructured":"Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL, Nowak MA (2005) Dynamics of chronic myeloid leukaemia. Nature 435(7046): 1267\u20131270","journal-title":"Nature"},{"issue":"10","key":"BFbjc2012142_CR23","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/nm1487","volume":"12","author":"I Roeder","year":"2006","unstructured":"Roeder I, Horn M, Glauche I, Hochhaus A, Mueller MC, Loeffler M (2006) Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med 12(10): 1181\u20131184","journal-title":"Nat Med"},{"issue":"2","key":"BFbjc2012142_CR24","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1182\/blood-2004-01-0282","volume":"105","author":"I Roeder","year":"2005","unstructured":"Roeder I, Kamminga LM, Braesel K, Dontje B, Haan Gd, Loeffler M (2005) Competitive clonal hematopoiesis in mouse chimeras explained by a stochastic model of stem cell organization. Blood 105(2): 609\u2013616","journal-title":"Blood"},{"issue":"8","key":"BFbjc2012142_CR25","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S0301-472X(02)00832-9","volume":"30","author":"I Roeder","year":"2002","unstructured":"Roeder I, Loeffler M (2002) A novel dynamic model of hematopoietic stem cell organization based on the concept of within-tissue plasticity. Exp Hematol 30(8): 853\u2013861","journal-title":"Exp Hematol"},{"issue":"1","key":"BFbjc2012142_CR26","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","volume":"109","author":"P Rousselot","year":"2007","unstructured":"Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O, Blanchet O, Marit G, Gluckman E, Reiffers J, Gardembas M, Mahon FX (2007) Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109(1): 58\u201360","journal-title":"Blood"},{"issue":"24","key":"BFbjc2012142_CR27","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362(24): 2251\u20132259","journal-title":"N Engl J Med"},{"issue":"9","key":"BFbjc2012142_CR28","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMra013339","volume":"346","author":"DG Savage","year":"2002","unstructured":"Savage DG, Antman KH (2002) Imatinib mesylate--a new oral targeted therapy. N Engl J Med 346(9): 683\u2013693","journal-title":"N Engl J Med"},{"issue":"24","key":"BFbjc2012142_CR29","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1056\/NEJMe1004430","volume":"362","author":"CL Sawyers","year":"2010","unstructured":"Sawyers CL (2010) Even better kinase inhibitors for chronic myeloid leukemia. N Engl J Med 362(24): 2314\u20132315","journal-title":"N Engl J Med"},{"key":"BFbjc2012142_CR30","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1182\/blood-2011-02-336685","volume":"118","author":"B Simonsson","year":"2011","unstructured":"Simonsson B, Gedde-Dahl T, Markevarn B, Remes K, Stentoft J, Almqvist A, Bjoreman M, Flogegard M, Koskenveesa P, Lindblom A, Malm C, Mustjoki S, Myhr-Eriksson K, Ohm L, Rasanen A, Sinisalo M, Sjalander A, Stromberg U, Weiss Bjerrum O, Ehrencrona H, Gruber F, Kairisto V, Olsson K, Sandin F, Nagler A, Lanng Nielsen J, Hjorth-Hansen H, Porkka K (2011) Combination of pegylated interferon-{alpha}2b with imatinib increases molecular response rates in patients with low or intermediate risk chronic myeloid leukemia. Blood 118: 3228\u20133235","journal-title":"Blood"},{"issue":"3","key":"BFbjc2012142_CR31","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.bbrc.2004.08.169","volume":"323","author":"N Sorel","year":"2004","unstructured":"Sorel N, Bonnet ML, Guillier M, Guilhot F, Brizard A, Turhan AG (2004) Evidence of ABL-kinase domain mutations in highly purified primitive stem cell populations of patients with chronic myelogenous leukemia. Biochem Biophys Res Commun 323(3): 728\u2013730","journal-title":"Biochem Biophys Res Commun"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2012142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2012142","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2012142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:07:07Z","timestamp":1684415227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2012142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,26]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["BFbjc2012142"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2012.142","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,26]]}}}